{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:51:48Z","timestamp":1790175108152,"version":"4.1.0"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"S 01","license":[{"start":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T00:00:00Z","timestamp":1514592000000},"content-version":"vor","delay-in-days":3042,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Baxter has developed a recombinant therapy for treating von Willebrand\u2018s disease. Recombinant VWF is co-expressed with the rFVIII in CHO cells used to produce the rFVIII product Advate. This rVWF is used as a drug component for a rVWF-rFVIII complex drug product. CHO cells produce partially processed and partially un-processed rVWF still containing the pro-peptide. In order to make a consistent preparation containing mature and processed rVWF only, rVWF is exposed to recombinant furin to remove the pro-peptide. Recombinant VWF and furin are produced under serum- and protein-free conditions. It is highly purified by a series of chromatographic steps and formulated in a protein-free buffer and has a homogeneous multimer distribution. The specific activity is higher in rVWF than in commercial plasma-derived VWF-FVIII complex products. SDS agarose electrophoretic analysis shows the presence of ultra-high molecular weight multimers. The FVIII-binding capacity and affinity of rVWF to FVIII is comparable to VWF in plasma. Carbohydrate analysis shows an intact glycosylation pattern. Recombinant VWF binds to collagen and promotes platelet adhesion under shear stress. It stabilizes endogenous FVIII in VWF-deficient knock-out mice as seen by a secondary rise in murine FVIII.<\/jats:p>","DOI":"10.1055\/s-0037-1617202","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T07:24:36Z","timestamp":1521703476000},"page":"S32-S38","source":"Crossref","is-referenced-by-count":18,"special_numbering":"S","title":["Development of a plasma- and albumin -free recombinant von Willebrand factor"],"prefix":"10.1055","volume":"29","author":[{"given":"P. L.","family":"Turecek","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mitterer","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. P.","family":"Matthiessen","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gritsch","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Varadi","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Siekmann","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Schnecker","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Plaimauer","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kaliwoda","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Purtscher","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Woehrer","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Mundt","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.-M.","family":"Muchitsch","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Suiter","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. M.","family":"Ewenstein","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"Ehrlich","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. P.","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Baxter BioScience, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,12,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","article-title":"Biochemistry and genetics of von Willebrand factor","volume":"67","author":"JE Sadler","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1160\/TH07-10-0592","article-title":"Plasma-derived biological medicines used to promote haemostasis","volume":"99","author":"FA Ofosu","year":"2008","journal-title":"Thromb Haemost"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00277-007-0343-1","article-title":"Prophylaxis in von Willebrand disease","volume":"86","author":"M Franchini","year":"2007","journal-title":"Ann Hematol"},{"issue":"S 01","key":"ref4","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.thromres.2007.03.013","article-title":"Treatment of urgent bleeding in von Willebrand disease","volume":"120","author":"JC Gill","year":"2007","journal-title":"Thromb Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"Von Willebrand disease (VWD): Evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"WL Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood.V57.6.1140.1140","article-title":"The complex multi-meric composition of factor VIII\/von Willebrand factor","volume":"57","author":"ZM Ruggeri","year":"1981","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0038-1661533","article-title":"Visualization of von Willebrand factor multimers by immunoenzymatic stain using avidin-biotin peroxidase complex","volume":"55","author":"M Aihara","year":"1986","journal-title":"Thromb Haemost"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1073\/pnas.95.16.9524","article-title":"A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis","volume":"95","author":"C Denis","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1538-7836.2008.03032.x","article-title":"rAHFPFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients","volume":"6","author":"VS Blanchette","year":"2008","journal-title":"J Thromb Haemost"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00418-001-0375-x","article-title":"In vivo and in vitro processing of recombinant pro-von Willebrand factor","volume":"117","author":"PL Turecek","year":"2002","journal-title":"Histochem Cell Biol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood.V94.5.1637","article-title":"Evidence for extracellular processing of pro-von Willebrand factor after infusion in animals with and without severe von Willebrand disease","volume":"94","author":"PL Turecek","year":"1999","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1470-8744.1996.tb00404.x","article-title":"Production of highly homogeneous and structurally intact recombinant von Willebrand factor multimers by furin-mediated propeptide removal in vitro","volume":"24","author":"U Schlokat","year":"1996","journal-title":"Biotechnol Appl Biochem"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"21948","DOI":"10.1016\/S0021-9258(18)54729-3","article-title":"The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII","volume":"266","author":"RJ Wise","year":"1991","journal-title":"J Biol Chem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1538-7836.2009.03453.x","article-title":"Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor","volume":"7","author":"K Varadi","year":"2009","journal-title":"J Thromb Haemost"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/j.1538-7836.2004.00838.x","article-title":"Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02\/150)","volume":"2","author":"AR Hubbard","year":"2004","journal-title":"J Thromb Haemost"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1055\/s-2006-947867","article-title":"Von Willebrand factor standards for plasma and concentrate testing","volume":"32","author":"AR Hubbard","year":"2006","journal-title":"Semin Thromb He-most"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2516.2004.00893.x","article-title":"A comparative in vitro evaluation of six von Willebrand factor concentrates","volume":"10","author":"S Lethagen","year":"2004","journal-title":"Haemophilia"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1055\/s-2006-949668","article-title":"Comparative analysis and classification of von Willebrand factor\/ factor VIII concentrates: impact on treatment of patients with von Willebrand disease","volume":"32","author":"U Budde","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"S 01","key":"ref19","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/01.mbc.0000167658.85143.49","article-title":"Management of von Willebrand disease with factor VIII\/von Willebrand factor concentrates: results from current studies and surveys","volume":"16","author":"AB Federici","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"S 03","key":"ref20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2516.2006.01273.x","article-title":"Von Willebrand\u2018s disease: clinical management","volume":"12","author":"AB Federici","year":"2006","journal-title":"Haemophilia"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2516.2005.01128.x","article-title":"Stability of lyophilized and reconstituted plasma\/albumin-free recombinant human factor VIII (ADVATE rAHFPFM)","volume":"11","author":"R Parti","year":"2005","journal-title":"Haemophilia"},{"key":"ref22","first-page":"555","article-title":"Anti-hemophilic factor (recombinant), plasma\/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A","volume":"3","author":"AD Shapiro","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0014-5793(95)01218-4","article-title":"Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinant furin","volume":"375","author":"BE Fischer","year":"1995","journal-title":"FEBS Lett"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1008030407679","article-title":"Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage","volume":"30","author":"A Preininger","year":"1999","journal-title":"Cytotechnology"},{"issue":"S 01","key":"ref25","first-page":"326a","article-title":"Cleavage of recombinant von Willebrand factor by a VWF-depolymerizing protease. Poster presented at the 38th Annual Meeting of the American Society of Hematology (ASH), Orlando, FL\/USA, Dec. 6\u201310, 1996","volume":"88","author":"PL Turecek","year":"1996","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00001721-199806000-00009","article-title":"Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease","volume":"9","author":"J Roussi","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1055\/s-2001-16892","article-title":"Recombinant von Willebrand factor: preclinical development","volume":"27","author":"B Plaimauer","year":"2001","journal-title":"Semin Thromb Hemost"},{"issue":"S 03","key":"ref28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2516.1998.0040s3053.x","article-title":"Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease","volume":"4","author":"HP Schwarz","year":"1998","journal-title":"Haemophilia"},{"key":"ref29","first-page":"181","article-title":"Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease","volume":"111","author":"HP Schwarz","year":"1999","journal-title":"Wien Klin Wochenschr"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/blood.V90.9.3555","article-title":"In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease","volume":"90","author":"PL Turecek","year":"1997","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-2002-27823","article-title":"Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease","volume":"28","author":"HP Schwarz","year":"2002","journal-title":"Semin Thromb Hemost"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0037-1617202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T23:49:44Z","timestamp":1758757784000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0037-1617202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":31,"journal-issue":{"issue":"S 01","published-online":{"date-parts":[[2017,12,30]]},"published-print":{"date-parts":[[2009,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0037-1617202","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}